LASER INDUCED HYPERTHERMIA TO TREAT CHOROIDAL MELANOMA

脉络膜黑色素瘤的正确治疗方法仍在争论中，但放射治疗 正在使用治疗（巩膜斑或外部束带电粒子） 作为越来越多患者的主要治疗方法。 二次 眼放射治疗的效果观察了几年后， 治疗，并可能导致视力显著下降。 眼热疗的辅助使用可减少电离辐射剂量， 脉络膜黑色素瘤需要放疗 如果生产 眼部热疗可以仅限于肿瘤， 眼辐射剂量可以反过来降低继发性 正常眼部结构的并发症。 我们的目标是记录使用低功率连续波的功效 （c.w.）YAG激光作为精确有效的眼科治疗源 肿瘤热疗 低功率，C.W. YAG激光器将不用于 消融、切割或光凝术。 相反，我们将利用 组织传输特性以及有效加热 c.w.的特点yag激光 a的经角膜递送 由YAG激光器产生的低功率红外光的发散光束 应该提供非常好的局部和受控的热疗 起源于脉络膜黑色素瘤的顶端 移植了脉络膜格林黑色素瘤的色素兔将 用于研究项目。 将确定肿瘤温度曲线 作为激光功率密度和肿瘤组织深度的函数。 眼部 YAG激光引起的毒性（治疗野内外） 将检查热疗并定量正常组织剂量反应 将生成曲线。 急性和慢性毒性将由 检眼镜观察、眼底照相、荧光素血管造影 和组织病理学检查。 定量剂量反应实验 也将进行比较巩膜斑块的有效性 （I-125）放射疗法到放射加热疗的组合。 各种治疗方法和剂量的有效性将根据 肿瘤再生长和肿瘤治愈参数。

The correct treatment for choroidal melanoma is under debate, but radiation therapy (scleral plaques or external beam charged particles) is being used as the primary therapy in an increasing number of patients. Secondary effects of ocular radiation therapy are observed several years after treatment and can result in a significant decrease in visual acuity. Adjunctive use of ocular hyperthermia could reduce the dose of ionizing radiation needed to sterilize choroidal melanomas. If the production of ocular hyperthermia can be limited only to the tumor, then a reduction in the dose of ocular radiation could in turn reduce the severity of secondary complications to normal ocular structures. Our goal is to document the efficacy of using a low power, continuous wave (c.w.) Neodymium YAG laser as a source of precise and efficient ocullar tumor hyperthermia. The low power, c.w. YAG laser will not be used in an ablative, cutting or photocoagulation procedure. Rather, we will exploit the tissue transmission properties as well as efficient heating characteristics of the c.w. YAG laser. Trans-corneal delivery of a diverging beam of low power infra-red light generated from the YAG laser should provide extremely well localized and controlled hyperthermia originating at the apex off a choroidal melanoma. Pigmented rabbits with transplanted choroidal Greene's melanoma will be used in research projects. Tumor temperature profiles will be determined as a function of laser light power density and tumor tissue depth. Ocular toxicity (both in and out of the treatment field) induced by YAG laser hyperthermia will be examined and quantitative normal tissue dose response curves will be generated. Acute and chronic toxicity will be documented by ophthalmoscopic observation, fundus photography, fluorescein angiography and histopathological examination. Quantitative dose response experiments will also be performed to compare the effectiveness of scleral plaque (I-125) radiation therapy to a combination of radiation plus hyperthermia. The effectiveness of various treatments and doses will be determined from tumor regrowth and tumor cure parameters.